Malignant Mesothelioma Market Report 2026

Malignant Mesothelioma Market Overview

• Malignant Mesothelioma market size has reached to $2.61 billion in 2025 • Expected to grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Increase In Clinical Research And Development Efforts Fueling The Growth Of The Market Due To Advancements In Diagnostics And Treatment Options • Market Trend: Monoclonal Antibodies Drive Innovation In Malignant Mesothelioma Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Malignant Mesothelioma Market?

Malignant mesothelioma is a rare and aggressive type of cancer that primarily affects the mesothelium, a thin layer of tissue that covers most of the internal organs. It most commonly develops in the lining of the lungs (pleura) but can also occur in the lining of the abdomen (peritoneum), heart (pericardium), or testicles. The main risk factor for developing malignant mesothelioma is exposure to asbestos, a mineral once widely used in construction and manufacturing. The main types of malignant mesothelioma are chemotherapy, radiation therapy, surgery, immunotherapy, and targeted therapy. Chemotherapy for malignant mesothelioma is a treatment that uses drugs to kill cancer cells, slow tumor growth, and help manage symptoms. It is often used when mesothelioma has spread beyond where surgery alone can be effective. The various routes of administration involved are oral, intravenous, injectable, and topical. The distribution channels involved are hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, which hospitals, oncology clinics, Rehabilitation centers, and research laboratories use.

What Is The Malignant Mesothelioma Market Growth Forecast?

The malignant mesothelioma market size is expected to see strong growth in the next few years. It will grow to $3.53 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to advancements in immunotherapy and targeted drugs, rising investment in rare cancer research, growing number of clinical trials, improved diagnostic technologies, increasing healthcare spending on oncology. Major trends in the forecast period include growing adoption of immunotherapy and targeted therapy, rising focus on multimodal treatment approaches, increasing demand for early and accurate diagnosis, expansion of specialized mesothelioma treatment centers, higher participation in clinical trials for rare cancers.

Global Malignant Mesothelioma Market Segmentation

1) By Treatment Type: Chemotherapy, Radiation Therapy, Surgery, Immunotherapy, Targeted Therapy 2) By Route Of Administration: Oral, Intravenous, Injectable 3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies 4) By End-User: Hospitals, Oncology Clinics Subsegments: 1) By Chemotherapy: Alkylating Agents, Antimetabolites, Combination Therapy 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Intensity-Modulated Radiation Therapy (IMRT), Stereotactic Body Radiation Therapy (SBRT), Proton Therapy 3) By Surgery: Pleurectomy Or Decortication (P/D), Extrapleural Pneumonectomy (EPP), Cytoreductive Surgery, Palliative Surgery 4) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Tumor Vaccines, Adoptive Cell Therapy 5) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Angiogenesis Inhibitors, Mesothelin-Targeted Agents, Gene Therapy-Based Approaches

What Is The Driver Of The Malignant Mesothelioma Market?

The increasing clinical research and development efforts are expected to drive the growth of the malignant mesothelioma market going forward. Clinical research and development (R&D) efforts involve conducting scientific studies and trials to develop new drugs, treatments, and medical devices. These efforts include testing new products' safety, efficacy, and potential side effects through controlled clinical trials. The increasing clinical research and development efforts are due to the growing demand for new and improved treatments, especially with the rising prevalence of chronic diseases and complex conditions. Research and development efforts drive malignant mesothelioma by accelerating advances in diagnostics, treatments, and targeted therapies, fostering innovative approaches to improve early detection, enhance survival rates, and develop more effective, less invasive treatment options. For instance, in January 2025, according to Anadolu Agency, a Turkey-based state-run news agency, clinical trials make up nearly 40% of the U.S. pharmaceutical research budget, totaling approximately $7 billion annually. Therefore, the increasing research and development efforts are driving the growth of the malignant mesothelioma industry.

Key Players In The Global Malignant Mesothelioma Market

Major companies operating in the malignant mesothelioma market are AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co. Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., Amgen Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Gilead Sciences Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bayer AG, Eisai Co. Ltd., Astellas Pharma Inc., Ono Pharmaceutical Co. Ltd., PharmaMar S.A.

Global Malignant Mesothelioma Market Trends and Insights

Major companies operating in the malignant mesothelioma market are focusing on developing advanced treatment options, such as monoclonal antibody treatments, to inhibit tumor growth and improve treatment precision. Monoclonal antibodies refer to laboratory-made proteins that mimic the immune system's ability to detect and target specific antigens, such as those found on cancer cells. For instance, in November 2023, Ono Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, received supplemental approval in Japan for the expanded use of Opdivo (nivolumab), a human anti-human PD-1 monoclonal antibody for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). This approval marks Opdivo as a new treatment option for this condition, where no standard treatments were previously established. Opdivo was designated an orphan drug for this indication, highlighting its potential to address a significant medical need.

What Are Latest Mergers And Acquisitions In The Malignant Mesothelioma Market?

In February 2024, AstraZeneca, a UK-based pharmaceutical company, acquired Gracell Biotechnologies for $1.2 billion. With this acquisition, AstraZeneca will take over all of Gracell's fully diluted share capital, including the shares represented by American depositary shares. Gracell Biotechnologies is a China-based that specializes in developing innovative cell therapies for cancer and autoimmune diseases, including malignant mesothelioma.

Regional Outlook

North America was the largest region in the malignant mesothelioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Malignant Mesothelioma Market?

The malignant mesothelioma market consists of revenues earned by entities by providing services such as genetic testing and biomarker analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The malignant mesothelioma market includes sales of radiation therapy equipment, biopsy kits, diagnostic imaging systems, genetic testing kits, and home healthcare equipment. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Malignant Mesothelioma Market Report 2026?

The malignant mesothelioma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the malignant mesothelioma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.